Inventor · disambiguated record
Vahe Bedian
Also filed as: BEDIAN VAHE
33 granted patents·27 pending applications·870 citations·filing 2002–2025
98Inventor score
Files withAMGEN FREMONT INC11VIRIDIAN THERAPEUTICS INC11PFIZER9BEDIAN VAHE7DIANTHUS THERAPEUTICS OPCO INC3
Top patents by PatentIndex Score
60 records- 0198US7338660B2Methods of treating cancer and enhancing immune responses with antibodies that bind CD40ABGENIX INC·Filed 2005·Granted Mar 4, 2008·144 cites·73 claims
- 0298US7326414B2Antibodies to M-CSFWARNER LAMBERT CO·Filed 2006·Granted Feb 5, 2008·86 cites·66 claims
- 0398US7288251B2Antibodies to CD40PFIZER·Filed 2002·Granted Oct 30, 2007·158 cites·22 claims
- 0497US7626012B2Nucleic acid molecules which encode antibodies that bind CD40AMGEN FREMONT INC·Filed 2008·Granted Dec 1, 2009·53 cites·21 claims
- 0597US7618633B2Antibodies that bind CD40 and methods of treating cancer and enhancing immune responsesAMGEN FREMONT INC·Filed 2007·Granted Nov 17, 2009·63 cites·45 claims
- 0697US7563442B2Antibodies to CD40 and methods of treating cancer and enhancing immune responsesABGENIX INC·Filed 2005·Granted Jul 21, 2009·62 cites·133 claims
- 0796US8388971B2Antibodies that bind CD40 and methods of treating cancer and enhancing immune responsesBEDIAN VAHE·Filed 2012·Granted Mar 5, 2013·32 cites·20 claims
- 0894US7728113B2Methods of treating arthritic conditions with antibodies to M-CSFAMGEN FREMONT INC·Filed 2007·Granted Jun 1, 2010·21 cites·27 claims
- 0993US11548951B1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2022·Granted Jan 10, 2023·7 cites·12 claims
- 1093US7537762B2Human monoclonal antibodies to activin receptor-like kinase-1AMGEN FREMONT INC·Filed 2006·Granted May 26, 2009·34 cites·15 claims
- 1193US7498420B2Antibodies to c-MetAMGEN FREMONT INC·Filed 2004·Granted Mar 3, 2009·60 cites·34 claims
- 1292US12404335B2Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2023·Granted Sep 2, 2025·2 cites·9 claims
- 1391US8192738B2Targeted antibodies directed to DLL4BEDIAN VAHE·Filed 2009·Granted Jun 5, 2012·16 cites·21 claims
- 1490US8821869B2Treatment methods using c-Met antibodiesAMGEN FREMONT INC·Filed 2013·Granted Sep 2, 2014·13 cites·15 claims
- 1590US8562985B2Antibodies to c-MetMICHAUD NEIL R·Filed 2012·Granted Oct 22, 2013·15 cites·21 claims
- 1689US7592430B2Antibodies to M-CSFAMGEN FREMONT·Filed 2004·Granted Sep 22, 2009·22 cites·52 claims
- 1788US7371378B2Modified human IGF-IR antibodiesPFIZER·Filed 2004·Granted May 13, 2008·28 cites·5 claims
- 1885US8398975B2Antibodies directed to αVβ6 and uses thereofRINKENBERGER JULIE·Filed 2010·Granted Mar 19, 2013·15 cites·9 claims
- 1985US8163280B2Antibodies to c-MetMICHAUD NEIL R·Filed 2009·Granted Apr 24, 2012·8 cites·18 claims
- 2085US8119130B2Targeted binding agents directed to KDR and uses thereof—035BARRY SIMON THOMAS·Filed 2008·Granted Feb 21, 2012·14 cites·4 claims
- 2184US2025313639A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2283US8507656B2Stabilized angiopoietin-2 antibodies and uses thereofBEDIAN VAHE·Filed 2009·Granted Aug 13, 2013·6 cites·15 claims
- 2383US2024043546A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2479US10280219B2Antibodies to M-CSFAMGEN FREMONT INC·Filed 2017·Granted May 7, 2019·1 cites·12 claims
- 2578US8188249B2Nucleic acid molecules encoding antibodies to M-CSFBEDIAN VAHE·Filed 2010·Granted May 29, 2012·2 cites·36 claims
- 2677US2022275096A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2775US2022267450A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2875US2022235137A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2974US12110344B2Antibodies that bind to cis and uses thereofDIANTHUS THERAPEUTICS OPCO INC·Filed 2023·Granted Oct 8, 2024·0 cites·25 claims
- 3074US2022267451A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3172US8080646B2Human monoclonal antibodies to activin receptor-like kinase-1NORTH MICHAEL AIDAN·Filed 2009·Granted Dec 20, 2011·3 cites·43 claims
- 3271US9221915B2Human monoclonal antibodies to activin receptor-like kinase-1BELOUSKI SHELLEY SIMS·Filed 2011·Granted Dec 29, 2015·3 cites·26 claims
- 3371US2025188188A1Antibodies that bind to c1s and uses thereofDIANTHUS THERAPEUTICS OPCO INC·Filed 2024·Application pending·0 cites
- 3470US8894998B2Antibodies directed to αVβ6 and uses thereofMEDIMMUNE LTD·Filed 2013·Granted Nov 25, 2014·1 cites·8 claims
- 3570US8663636B2Method of treating a malignant tumor by administering antibodies directed to DLL4FOLTZ IAN·Filed 2012·Granted Mar 4, 2014·1 cites·5 claims
- 3670US2010098694A1Antibodies to cd40AMGEN FREMONT INC·Filed 2009·Application pending·0 cites
- 3769US2019202905A1Antibodies to m-csfAMGEN FREMONT INC·Filed 2019·Application pending·0 cites
- 3868US12252550B2Antibodies that bind to C1S and uses thereofDIANTHUS THERAPEUTICS OPCO INC·Filed 2022·Granted Mar 18, 2025·0 cites·21 claims
- 3968US2024343814A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4068US2024352133A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4168US2024360227A1Compositions and methods for treatment of thyroid eye diseaseVIRIDIAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4267US2005136055A1CD40 antibody formulation and methodsPFIZER·Filed 2004·Application pending·0 cites
- 4367US2009311254A1Cd40 antibody formulation and methodsPFIZER·Filed 2009·Application pending·0 cites
- 4462US9718883B2Antibodies to M-CSFAMGEN FREMONT INC·Filed 2015·Granted Aug 1, 2017·0 cites·39 claims
- 4562US9206255B2Nucleic acid molecule encoding target antibodies directed to DLL4MEDIMMUNE LLC·Filed 2014·Granted Dec 8, 2015·0 cites·10 claims
- 4662US2013024956A1Antibodies to cd40PFIZER·Filed 2012·Application pending·0 cites
- 4761US7575746B2Modified human IGF-IR antibodiesPFIZER·Filed 2008·Granted Aug 18, 2009·0 cites·12 claims
- 4861US2012263732A1Cd40 antibody formulation and methodsGLADUE RONALD P·Filed 2012·Application pending·0 cites
- 4960US2012244167A1Antibodies to m-csfBEDIAN VAHE·Filed 2012·Application pending·0 cites
- 5059US2016152713A1Antibodies to cd40AMGEN FREMONT INC·Filed 2015·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Vahe Bedian files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →